[代谢性骨病:2024年的新动向]。

Elena Gonzalez Rodriguez, Hanene Lassoued, Olivier Lamy
{"title":"[代谢性骨病:2024年的新动向]。","authors":"Elena Gonzalez Rodriguez, Hanene Lassoued, Olivier Lamy","doi":"10.53738/REVMED.2025.21.900-1.45","DOIUrl":null,"url":null,"abstract":"<p><p>The epidemiology of femoral fractures is changing, with more femoral shaft fractures linked to high-risk physical exercise by an older population. Vitamin D given during pregnancy for the mother's health could benefit the child. Zoledronic acid is the most effective bisphosphonate. It should be given during hospitalization to people suffering from hip fractures. Denosumab should not be used in patients with severe renal failure. When denosumab is discontinued, management of the rebound effect requires bone resorption markers to be kept at very low levels to maintain the bone mass gained as much as possible. Finally, progress continues to be made in the treatment of rare bone diseases.</p>","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 900-1","pages":"45-48"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Metabolic bone diseases : what's new in 2024].\",\"authors\":\"Elena Gonzalez Rodriguez, Hanene Lassoued, Olivier Lamy\",\"doi\":\"10.53738/REVMED.2025.21.900-1.45\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The epidemiology of femoral fractures is changing, with more femoral shaft fractures linked to high-risk physical exercise by an older population. Vitamin D given during pregnancy for the mother's health could benefit the child. Zoledronic acid is the most effective bisphosphonate. It should be given during hospitalization to people suffering from hip fractures. Denosumab should not be used in patients with severe renal failure. When denosumab is discontinued, management of the rebound effect requires bone resorption markers to be kept at very low levels to maintain the bone mass gained as much as possible. Finally, progress continues to be made in the treatment of rare bone diseases.</p>\",\"PeriodicalId\":21286,\"journal\":{\"name\":\"Revue medicale suisse\",\"volume\":\"21 900-1\",\"pages\":\"45-48\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue medicale suisse\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53738/REVMED.2025.21.900-1.45\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale suisse","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53738/REVMED.2025.21.900-1.45","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

股骨骨折的流行病学正在发生变化,更多的股骨骨干骨折与老年人的高风险体育锻炼有关。在怀孕期间为母亲的健康服用维生素D对孩子也有好处。唑来膦酸是最有效的二膦酸盐。髋部骨折患者住院期间应服用。Denosumab不应用于严重肾功能衰竭患者。当停用denosumab时,为了控制反弹效应,需要将骨吸收标志物保持在非常低的水平,以尽可能地维持增加的骨量。最后,在治疗罕见骨病方面继续取得进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Metabolic bone diseases : what's new in 2024].

The epidemiology of femoral fractures is changing, with more femoral shaft fractures linked to high-risk physical exercise by an older population. Vitamin D given during pregnancy for the mother's health could benefit the child. Zoledronic acid is the most effective bisphosphonate. It should be given during hospitalization to people suffering from hip fractures. Denosumab should not be used in patients with severe renal failure. When denosumab is discontinued, management of the rebound effect requires bone resorption markers to be kept at very low levels to maintain the bone mass gained as much as possible. Finally, progress continues to be made in the treatment of rare bone diseases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revue medicale suisse
Revue medicale suisse Medicine-Medicine (all)
CiteScore
0.60
自引率
0.00%
发文量
1210
期刊介绍: Destinée aux professionnels de santé, la plateforme revmed.ch regroupe la version électronique de la Revue Médicale Suisse et les applications de formation et d"aide à la prise de décision eRMS. La eRMS est le fruit d’une large collaboration entre institutions et praticiens de Suisse romande.
期刊最新文献
[Clinical and public health challenges of crack consumption]. [Forced returns of asylum seekers in Switzerland : a call for more humanity]. [Infectious disease screening of asylum seekers and refugees in Switzerland]. [Prevention and health promotion strategies for homeless people]. [Promoting sexual health at a local scale. The exemple of the Antenne santé sexuelle Onex].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1